Indeed, the raison d'être of the “HER2-low classification” in the DB-04 trial was to provide a simplified reference for the inclusion criteria of BC that were enrolled in the study based on specific criteria (i.e., IHC score 1 + or 2 + /ISH negative) for treatment with T-DXd. This evidence concerns the gene ERBB2 and breast cancer.